John is Managing Director of Newstar Ventures Ltd, an investment and advisory firm. Recent transaction experience include Acacia Pharma (Euronext IPO), Benitec Biopharma (US IPO), Adalta and Sienna Cancer Diagnostics (Australian IPO's), Medistem (acquired by Intrexon), Arana (acquired by Cephalon) , Domantis (acquired by GSK) and FVSystems (acquired by GoDaddy). Prior to Newstar, John was head of the Government backed $300M ITI Life Sciences Investment Fund, based in the UK.
Cliff brings over 25 years of life science industry experience to Scancell in the development and commercialisation of emerging technologies and therapeutic products including licensing, M&A, corporate financing and operations management. Most recently he was Chief Business and Operating Officer of Benitec Biopharma Ltd (ASX:BLT, NASDAQ:BNTC). Prior to his role at Benitec he held the position of Managing Director at Sienna Cancer Diagnostics Ltd (ASX:SDX), and also for therapeutic antibody development companies Immune System Therapeutics Ltd and Biosceptre International Ltd. He was formerly VP of Business Development at Arana Therapeutics Ltd, which was acquired by US-based Cephalon Inc (now Teva) in 2009, and he is currently a director of investment fund Newstar Ventures Pty Ltd. Cliff holds a Bachelor of Pharmacy and a PhD in Medicinal Chemistry from the University of Nottingham.
Lindy is an internationally recognised immunologist in the field of tumour therapy, She has worked for over 20 years in translational research, developing products for clinical trials including monoclonal antibodies for diagnostic imaging and therapy and cancer vaccines. She has a personal Chair in Cancer Immunotherapy at the Department of Clinical Oncology at the University of Nottingham.
Dr Sally Adams was Head of Neurology & Virology at British Biotech and Development Director at Neures Limited before becoming an independent consultant providing drug development and management services within the biotechnology and pharmaceutical sectors, specialising in biological entities. She has worked on many complex projects over the past 25 years including anti-infective vaccines, cancer immunotherapies and an innovative stem cell treatment for visual dysfunction. Sally previously worked as a development consultant to Scancell, providing guidance on the development of SCIB1, before her appointment as Development Director in May 2014.
Richard was formerly in senior management at Astra where he ran international clinical trials on Astra’s gastrointestinal and cardiovascular products including omeprazole before becoming Director of international Product Marketing. Thereafter he co-founded Paradigm Therapeutics (acquired by Takeda) and was a Board Director of Enact Pharma (acquired by Protherics/BTG) before co-founding Scancell with Lindy Durrant.
Matthew started his career as a clinical and research scientist before moving to venture capital in 1999. He originally joined Oxford Technology Management making seed investments into start-up and early stage technology companies, predominantly in healthcare. More recently, he co-founded Longwall Venture Partners, an early-stage technology investment company with £70m under management. Matthew has a DPhil in Biochemistry from the University of Oxford.
Alan has a proven track record in the US life sciences industry and is currently President and CEO of DiaVacs, a San Diego based clinical stage biotechnology company. He has held senior positions at a number of life science companies including Celgene, Ambit Biosciences, Medistem, Novocell and Signal Therapeutics. Whilst CEO at Signal Therapeutics Alan oversaw multi-year alliances with leading pharmaceutical companies including Akzo Nobel, Roche Biosciences and Novartis and subsequently managed its $275 million acquisition by Celgene. He is also on the Board of Directors of NASDAQ listed companies Biomarin and Assembly Biosciences.
Cliff Holloway, CEO of Scancell Holdings PLC (LON:SCLP), speaks to Proactive London's Andrew Scott after announcing they're to kick off the UK arm of the phase II clinical trial of its flagship skin cancer drug.
The study will test the safety and efficacy of SCIB1 in 25 metastatic melanoma patients who are also receiving Merck’s checkpoint inhibitor Pembrolizumab.
Thu, 25 Apr 2019 10:56:00
The mid-stage study is testing Scancell’s flagship skin cancer immunotherapy in combination with Keytruda – the blockbuster checkpoint inhibitor developed by Merck
Thu, 25 Apr 2019 12:20:00
It follows on from similar awards in key markets such as the US, Europe, South Africa and Australia
Mon, 08 Apr 2019 08:20:00